Shang Hai Zheng Quan Bao·2025-08-20 19:31Core Points - The company, CanSino Biologics, has approved the use of temporarily idle raised funds for cash management, with a maximum amount of 340 million yuan, ensuring that it does not affect the implementation of fundraising projects [7][10][20] - The company reported a total fundraising amount of 5.200 billion yuan from its initial public offering, with a net amount of approximately 4.979 billion yuan after deducting issuance costs [25][26] - As of June 30, 2025, the company has utilized approximately 4.722 billion yuan of the raised funds, leaving a balance of about 261.87 million yuan [26][30] Financial Data - The total amount raised from the public offering was 5.200 billion yuan, with a net amount of 4.979 billion yuan after costs [25][26] - The company has generated approximately 240.82 million yuan in interest income and cash management income from the raised funds [26] - The company has used 4.721 billion yuan of the raised funds, with 294.5 million yuan allocated for cash management [26][34] Fund Management - The company has established a fundraising management system to ensure the proper use and supervision of the raised funds [27] - A tripartite supervision agreement has been signed with the underwriter and banks to manage the raised funds [28] - The company plans to invest temporarily idle funds in safe, liquid, and guaranteed investment products, including structured deposits and wealth management products [11][20] Project Updates - The company has made changes to some fundraising projects, reallocating funds to the CanSino Innovation Vaccine Industrial Park project [38][39] - The expected completion date for the Innovation Vaccine Industrial Park project has been postponed from December 2024 to December 2026 [41] - There are no remaining unallocated funds from the over-raised capital as of June 30, 2025 [36][42]